Search Results - "Lemech, C"

923MO First results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors.

Authors: Yap, T.A. Lemech, C. Voskoboynik, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS603-S604. 2p.

2780P BL0020, a novel targeting tumor microenvironment (TME) nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Results from a phase I study.

Authors: Wang, S. Lemech, C. Li, N. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1479-S1479. 1p.

1545P CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: An open-label, multicenter, phase I first-in-human study.

Authors: Lemech, C. Coward, J. Gao, B. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS923-S923. 1p.

678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations.

Authors: Lemech, C. Luke, J.J. Falchook, G.S. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS528-S529. 2p.

576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study.

Authors: Gong, J. Lemech, C. Day, D. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS467-S468. 2p.

676TiP MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors.

Authors: Lemech, C. Kichenadasse, G. Teng, C. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS528-S528. 1p.

345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study.

Authors: Lemech, C. Sun, Y. Nagrial, A. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS360-S360. 1p.

1168PPhase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors.

Authors: Coward, J Lemech, C Meniawy, T et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Biomarker development in endometrial cancer : circulating tumour cells, tissue methylation and genotyping studies

Authors: Lemech, C. R.

URL: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.647305

747P Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors.

Authors: Falchook, G.S. Fu, S. Lemech, C. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS885-S886. 2p.

1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors.

Authors: Tran, B. Millward, M. Lemech, C. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS635-S635. 1p.

711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors.

Authors: Weickhardt, A.J. Frentzas, S. Lemech, C. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS492-S492. 1p.

1316eTiP A phase Ib trial of CS5001 (ROR1-ADC) as a single agent and in combination with systemic therapies in patients with advanced solid tumours and lymphomas.

Authors: Song, Y. Xie, L. Zhang, Y. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS822-S823. 2p.

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer.

Authors: Strickler, J. H. Satake, H. George, T. J. et al.

Source: New England Journal of Medicine. 1/5/2023, Vol. 388 Issue 1, p33-43. 11p.

991P PANNA-COTA (Practical assessment of NECTA network assistance in cancer outpatient trials access): A prospective investigator-led trial using ctDNA to inform early phase trial matching.

Authors: Liu, J.J. Farrow, M. Hsing, S. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS649-S649. 1p.

57O A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors.

Authors: Cheng, Y. Wu, L. Parsonson, A. et al.

Source: Annals of Oncology. 2024 Supplement 4, Vol. 35, pS1426-S1426. 1p.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Authors: Soria, J. C. Gan, H. K. Blagden, S. P. et al.

Source: Annals of Oncology. Dec2016, Vol. 27 Issue 12, p2268-2274. 7p. 5 Charts, 2 Graphs.

Novel Use of Micra AV Pacemaker for Immune Checkpoint Inhibitor-associated Myocarditis, Life-sustaining Ventricular Tachycardia and Atrioventricular Dissociation.

Authors: Vickers, D. Port, K. Li, J. et al.

Source: Heart, Lung & Circulation. Jul2023:Supplement 3, Vol. 32, pS343-S343. 1p.

1197TiP A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

Authors: Lee, D.H. Roohullah, A. Cho, B.C. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1096-S1096. 1p.

1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing.

Authors: Markman, B. Day, D. Park, J.J.W. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS722-S722. 1p.